These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 32737111)

  • 1. COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine.
    Teh CL; Cheong YK; Wan Musa WR; Wan Mohd Akbar SA; Mat Husin N; Gun SC
    Ann Rheum Dis; 2021 May; 80(5):e69. PubMed ID: 32737111
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to: 'COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine' by Teh
    Mathian A; Amoura Z
    Ann Rheum Dis; 2021 May; 80(5):e70. PubMed ID: 32737109
    [No Abstract]   [Full Text] [Related]  

  • 3. Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics.
    Mendel A; Bernatsky S; Askanase A; Bae SC; Clarke AE; Costedoat-Chalumeau N; Gladman DD; Gordon C; Hanly J; Jacobsen S; Kalunian K; Mak A; Mosca M; Pons-Estel BA; Ruiz-Irastorza G; Urowitz M; Vinet É
    Ann Rheum Dis; 2021 Feb; 80(2):1-2. PubMed ID: 32586918
    [No Abstract]   [Full Text] [Related]  

  • 4. Comment on 'Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19' by Konig
    Sbidian E; Penso L; Herlemont P; Botton J; Baricault B; Semenzato L; Drouin J; Weill A; Dray-Spira R; Zureik M
    Ann Rheum Dis; 2023 May; 82(5):e117. PubMed ID: 32859610
    [No Abstract]   [Full Text] [Related]  

  • 5. Hydroxychloroquine, TTP, COVID-19, and SLE.
    Sookaromdee P; Wiwanitkit V
    Turk J Haematol; 2021 Feb; 38(1):99-100. PubMed ID: 33401889
    [No Abstract]   [Full Text] [Related]  

  • 6. Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus.
    Jakhar D; Kaur I
    Nat Med; 2020 May; 26(5):632. PubMed ID: 32269358
    [No Abstract]   [Full Text] [Related]  

  • 7. Hydroxychloroquine shortages during the COVID-19 pandemic.
    Mendel A; Bernatsky S; Thorne JC; Lacaille D; Johnson SR; Vinet É
    Ann Rheum Dis; 2021 Mar; 80(3):e31. PubMed ID: 32434820
    [No Abstract]   [Full Text] [Related]  

  • 8. Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey.
    Plüß M; Chehab G; Korsten P
    Ann Rheum Dis; 2021 Apr; 80(4):e52. PubMed ID: 32616604
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine.
    Carbillon L; Benbara A; Boujenah J
    Ann Rheum Dis; 2021 Apr; 80(4):e54. PubMed ID: 32475831
    [No Abstract]   [Full Text] [Related]  

  • 10. Response to: 'Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine' by Carbillon
    Konig MF; Gianfrancesco M; Yazdany J; Robinson PC
    Ann Rheum Dis; 2021 Apr; 80(4):e55. PubMed ID: 32475834
    [No Abstract]   [Full Text] [Related]  

  • 11. No evidence so far on the protective effect of hydroxychloroquine to prevent COVID-19: comment by Joob and Wiwanitkit.
    Romão VC; Cruz-Machado AR; Fonseca JE
    Ann Rheum Dis; 2021 Feb; 80(2):e22. PubMed ID: 32404340
    [No Abstract]   [Full Text] [Related]  

  • 12. Response to: 'Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey' by Plüß
    Mathian A; Amoura Z
    Ann Rheum Dis; 2021 Apr; 80(4):e53. PubMed ID: 32616603
    [No Abstract]   [Full Text] [Related]  

  • 13. Systematic analysis of COVID-19 infection and symptoms in a systemic lupus erythematosus population: correlation with disease characteristics, hydroxychloroquine use and immunosuppressive treatments.
    Gendebien Z; von Frenckell C; Ribbens C; André B; Thys M; Gangolf M; Seidel L; Malaise MG; Malaise O
    Ann Rheum Dis; 2021 Jun; 80(6):e94. PubMed ID: 32586921
    [No Abstract]   [Full Text] [Related]  

  • 14. Hydroxychloroquine cardiotoxicity: a case-control study comparing patients with COVID-19 and patients with systemic lupus erythematosus.
    Mancuso S; Spinelli FR; Agati L; Ciardi MR; Garufi C; Natalucci F; Molteni E; Truglia S; Riccieri V; Priori R; Mastroianni CM; Conti F
    Clin Exp Rheumatol; 2022 May; 40(5):890-896. PubMed ID: 35383554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine'.
    Gupta S; Nakabo S; Chu J; Hasni S; Kaplan MJ
    Ann Rheum Dis; 2023 Oct; 82(10):e215. PubMed ID: 33452005
    [No Abstract]   [Full Text] [Related]  

  • 16. Correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine'.
    Martelli Júnior H; Marques NP; Marques NCT; Gomes de Lucena E; Martelli DRB; Oliveira EA
    Ann Rheum Dis; 2023 Nov; 82(11):e225. PubMed ID: 33883160
    [No Abstract]   [Full Text] [Related]  

  • 17. Possible Consequences of a Shortage of Hydroxychloroquine for Patients with Systemic Lupus Erythematosus amid the COVID-19 Pandemic.
    Peschken CA
    J Rheumatol; 2020 Jun; 47(6):787-790. PubMed ID: 32269064
    [No Abstract]   [Full Text] [Related]  

  • 18. Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review.
    He F; Luo Q; Lei M; Fan L; Shao X; Hu K; Qin S; Yu N; Cao J; Yang L
    Clin Rheumatol; 2020 Sep; 39(9):2803-2810. PubMed ID: 32725351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxychloroquine and COVID-19: can we learn from the use of rituximab in systemic lupus erythematosus?
    Lekpa FK; Ngahane BHM; Njonnou SRS; Fouda H; Halle MP; Njankouo YM; Dzudie A; Choukem SP; Luma HN
    Pan Afr Med J; 2021; 38():372. PubMed ID: 34367451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19 occurrence in one secukinumab-treated patient affected by hidradenitis suppurativa and systemic lupus erythematosus.
    Chiricozzi A; Garcovich S; Malvaso D; Giovanardi G; Peris K
    Int J Dermatol; 2020 Nov; 59(11):1423-1424. PubMed ID: 32966593
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.